- Home
- ANVS vs ALGS Comparison
ANVS vs ALGS Comparison
Compare ANVS & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- ALGS
- Stock Information
- Founded
- ANVS 2008
- ALGS 2018
- Country
- ANVS United States
- ALGS United States
- Employees
- ANVS N/A
- ALGS N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- ALGS Health Care
- Exchange
- ANVS Nasdaq
- ALGS Nasdaq
- Market Cap
- ANVS 55.5M
- ALGS 53.0M
- IPO Year
- ANVS 2020
- ALGS 2020
- Fundamental
- Price
- ANVS $2.74
- ALGS $7.70
- Analyst Decision
- ANVS Strong Buy
- ALGS Strong Buy
- Analyst Count
- ANVS 4
- ALGS 1
- Target Price
- ANVS $18.00
- ALGS $70.00
- AVG Volume (30 Days)
- ANVS 277.6K
- ALGS 62.6K
- Earning Date
- ANVS 08-12-2025
- ALGS 08-06-2025
- Dividend Yield
- ANVS N/A
- ALGS N/A
- EPS Growth
- ANVS N/A
- ALGS N/A
- EPS
- ANVS N/A
- ALGS N/A
- Revenue
- ANVS N/A
- ALGS $3,174,000.00
- Revenue This Year
- ANVS N/A
- ALGS N/A
- Revenue Next Year
- ANVS N/A
- ALGS $51.55
- P/E Ratio
- ANVS N/A
- ALGS N/A
- Revenue Growth
- ANVS N/A
- ALGS N/A
- 52 Week Low
- ANVS $1.11
- ALGS $3.76
- 52 Week High
- ANVS $10.54
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- ANVS 52.55
- ALGS 46.70
- Support Level
- ANVS $2.58
- ALGS $7.31
- Resistance Level
- ANVS $2.94
- ALGS $7.85
- Average True Range (ATR)
- ANVS 0.21
- ALGS 0.75
- MACD
- ANVS -0.00
- ALGS -0.09
- Stochastic Oscillator
- ANVS 64.41
- ALGS 35.03
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.